Efficacy News and Research

RSS
New nanoparticle SARS-CoV-2 vaccine confers robust protection with single dose after two weeks

New nanoparticle SARS-CoV-2 vaccine confers robust protection with single dose after two weeks

Can universal vaccines and treatments against future SARS-CoV-2 variants be developed?

Can universal vaccines and treatments against future SARS-CoV-2 variants be developed?

Researchers Identify potent small molecule inhibitors against SARS-CoV-2

Researchers Identify potent small molecule inhibitors against SARS-CoV-2

Stay-at-home measures may have offered protective effects for youth mental health early in the pandemic

Stay-at-home measures may have offered protective effects for youth mental health early in the pandemic

Researchers offer large-scale screening of potential broad-spectrum SARS-CoV-2 antivirals

Researchers offer large-scale screening of potential broad-spectrum SARS-CoV-2 antivirals

Study investigates the efficacy of COVID-19 vaccines over longer term

Study investigates the efficacy of COVID-19 vaccines over longer term

Study finds vaccine distrust among majority of incarcerated people

Study finds vaccine distrust among majority of incarcerated people

HCAs are a promising risk indicator of type 2 diabetes

HCAs are a promising risk indicator of type 2 diabetes

COVID-19: Several 'proxy wars' spawned by the pandemic

COVID-19: Several 'proxy wars' spawned by the pandemic

Study discovers new target on SARS-CoV-2 spike for protective antibodies

Study discovers new target on SARS-CoV-2 spike for protective antibodies

Analysis finds low adherence to UK's test, trace, and isolate system

Analysis finds low adherence to UK's test, trace, and isolate system

Researchers develop a recombinant SARS-CoV-2 receptor-binding domain trimer vaccine candidate

Researchers develop a recombinant SARS-CoV-2 receptor-binding domain trimer vaccine candidate

COVID-19 vaccine acceptance in pregnancy

COVID-19 vaccine acceptance in pregnancy

Antibodies produced from infection with SARS-CoV-2 501Y.V2 protect against other variants

Antibodies produced from infection with SARS-CoV-2 501Y.V2 protect against other variants

Oxford-AstraZeneca vaccine effective against B.1.1.7 SARS-CoV-2 variant

Oxford-AstraZeneca vaccine effective against B.1.1.7 SARS-CoV-2 variant

Risk of SARS-CoV-2 from reinfected individuals with previous infection or vaccination

Risk of SARS-CoV-2 from reinfected individuals with previous infection or vaccination

Tamper-proof temperature indicator could help monitor ideal storage conditions of mRNA vaccines

Tamper-proof temperature indicator could help monitor ideal storage conditions of mRNA vaccines

Cancer patients treated with immunotherapy at high risk of developing thrombotic complications

Cancer patients treated with immunotherapy at high risk of developing thrombotic complications

New mRNA COVID-19 vaccine candidate shows promise in vivo

New mRNA COVID-19 vaccine candidate shows promise in vivo

Researchers evaluate antibodies that inhibit SARS-CoV-2 RBD variants with a novel assay

Researchers evaluate antibodies that inhibit SARS-CoV-2 RBD variants with a novel assay

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.